Data as of Dec 24
| -0.12 / -1.08%|
The 4 analysts offering 12-month price forecasts for ADMA Biologics Inc have a median target of 18.00, with a high estimate of 20.00 and a low estimate of 17.50. The median estimate represents a +63.93% increase from the last price of 10.98.
The current consensus among 4 polled investment analysts is to Buy stock in ADMA Biologics Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.